<DOC>
	<DOCNO>NCT02891213</DOCNO>
	<brief_summary>Systemic Lupus Erythematosus ( SLE ) common systemic autoimmune disease . The clinical manifestation severe affect multiple target organ kidney , central nervous system , skin , heart joint . Despite progress make therapeutic approach new immunosuppressive regimen , morbi-mortality still high . Therefore , 's important identify new biomarkers help clinician predict severity evolution disease good adaptation treatment try improve prognosis . RAGE ( Receptor Advanced Glycation Endproducts ) : RAGE ( Receptor Advanced Glycation Endproducts ) ubiquitous membrane receptor , involve development many disease diabetes , chronic renal failure also vascular remodelling , inflammatory , infectious deseases cancer . RAGE regulate number crucial cell process like inflammation , tissue cellular homeostasis . RAGE able bind advance glycation end product ( AGEs ) pentosidine , carboxymethyllysine ( CML ) , methyl-glyoxal-hydroimidazolone-1 ( MG- H1 ) , also ligands HMGB1 ( high mobility group box1 ) , S100A8/A9 proteins correlate recent study activity index SLE . The activation RAGE lead cascade intracellular signal activation transcription factor NF-ΚB . NF-ΚB enable traduction proinflammatory cytokine IL-6 , IL-1α , IFN-γ . In SLE , cytokine involve perpetuation inflammation tissue damage include lupus nephritis . Moreover , activation RAGE induce expression adhesion molecule sICAM -1 sVCAM -1 wich recently involve SLE vasculitis . Soluble form RAGE , sRAGE esRAGE : RAGE proinflammatory membrane receptor . But RAGE also exist soluble plasma form , esRAGE ( secreted form ) sRAGE ( truncated form cleave MMP9 ADAM10 enzymes ) . esRAGE sRAGE ligand-binding specificity RAGE may function 'decoy receptor ' bind pro-inflammatory ligand prevent access cell surface RAGE ( Kierdorf Fritz , 2013 ) . Therefore , soluble form anti-inflammatory action . Several study show decrease circulating level sRAGE patient Rheumatoid Arthritis , Sjögren Syndrome compare healthy control . However , role RAGE SLE remain unknown . RAGE Systemic Lupus Erythematosus , recent advance : Our team ( Laboratory Nephrology , CNRS UMR 7369 , URCA ) show study lupus RAGE knockout mouse ( B6/ MRL-FAS lpr/J RAGE-/- ) strong involvement RAGE systemic manifestation SLE . Recently , another report show sRAGE anti-inflammatory effect lupus nephritis could potent therapy mouse . In human , two study show correlation plasma level sRAGE lupus phenotype ( Nienhuis et al . , 2008 ) . Working hypothesis : Based result current study , investigator think RAGE axis soluble form play crucial role complex pathogenesis SLE . The investigator hypothesize plasma level sRAGE esRAGE reflection activity development SLE human . Soluble form RAGE ligands may novel biomarkers SLE sRAGE potent therapeutic target .</brief_summary>
	<brief_title>Study Role Soluble Forms RAGE ( sRAGE/esRAGE ) Diagnostic Prognostic Biomarkers Systemic Lupus Erythematosus .</brief_title>
	<detailed_description>Expected result : The investigator expect correlation serum sRAGE , esRAGE activity SLE presence visceral involvement . Furthermore study allow u analyze first time lupus population , correlation soluble form RAGE ( esRAGE , sRAGE ) cytokines molecule involve lupus visceral involvement IL-6 , IL-1α , IFN-γ , sICAM-1 sVCAM-1 . Completion project , allow well understanding role RAGE RAGE ligand SLE activity provide rationale prospective study . Future perspective include assessment risk-benefit use anti-RAGE strategy recombinant sRAGE/esRAGE molecule adjuvant treatment SLE . Study Design : investigator design retrospective , analytic , transversal , mulitcentric study . investigator would like use serum clinical information collect `` Lupus BioBanque du Rhin Supérieur '' ( LBBR UF 9882 ) measure soluble form RAGE , RAGE-ligands , cytokine , sICAM sVCAM . The investigator would like include 150 patient study . Aim 1 : The main objective study investigate association Systemic Lupus Erythematosus ( SLE ) activity measure SLEDAI score serum concentration sRAGE esRAGE . Aim 2 : The study correlation activity activity marker SLE soluble form RAGE : 1. concentration RAGE ligands ( AGEs like CML , pentosidine MG-H1 ) soluble form RAGE ( esRAGE , sRAGE ) 2. cytokine profile ( IL-6 , IL-1α , IFN-γ ) soluble form RAGE ( esRAGE , sRAGE ) 3 . The concentration sICAM-1 sVCAM-1 soluble form RAGE ( esRAGE , sRAGE ) Methods : Inclusion criterion : - LBBR inclusion criterion - Absence immunomodulatory treatment , - preserve renal function ( MDRD &gt; 60ml/min ) . Exclusion criterion : - renal failure define MDRD clearance &lt; 60 mL/min/m2 , - neoplasia , - diabetes , - autoimmune disease , - current immunosuppressive treatment . Data collection : About 500 μl serum necessary patient make measurement . Mass spectrometry use measurement RAGE ligands ( Advanced glycation end product CML , pentosidine MG-H1 ) . Commercially available ELISA kit use measurement sRAGE , esRAGE , sVCAM1 . Flow Cytometry use measurement cytokine ( IL-6 , IL-1a , IFN-y ) sICAM1 .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>patient include LBBR biobank absence immunomodulatory treatment , preserve renal function ( MDRD &gt; 60ml/min ) . renal failure define MDRD clearance &lt; 60 mL/min/m2 , neoplasia , diabetes , autoimmune disease , current immunosuppressive treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>